Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

Jennifer A. Wargo¹,², Zachary A. Cooper¹,², and Keith T. Flaherty³

ABSTRACT

There have been significant advances in the past several years with regard to targeted therapy and immunotherapy for cancer. This is highlighted in melanoma, where treatment with targeted therapy (against the BRAF oncoprotein) results in responses in the majority of patients, although the duration of response is limited. In contrast, treatment with immunotherapy results in a lower response rate, but one that tends to be more durable. Insights about mechanisms of response and potential synergy between these treatment strategies for melanoma are a focus of this review, with opportunities to extend these insights to the treatment of other cancers.

Significance: Two major advances in melanoma have occurred concurrently and involve treatment with targeted therapy and immune checkpoint blockade. However, each of these approaches has limitations with regard to overall response rates or duration of response. To address this, investigators have proposed combining these strategies, and this concept is being tested empirically in clinical trials. There is a scientific rationale supporting the combination of targeted therapy and immunotherapy, and these concepts are discussed herein.

INTRODUCTION

Within the past decade, key oncogenic mutations have been identified in melanoma and other cancers that not only contribute to their malignant potential but may also serve as targets for therapy. Mutations in the BRAF gene occur in about half of melanomas (1) and lead to constitutive signaling through the MAPK pathway. Treatment of BRAF-mutant melanoma with agents targeting this oncogenic mutation represents one of the most significant advances in melanoma care in decades. Results from a phase III trial of single-agent BRAF inhibitor versus standard-of-care chemotherapy showed a significant improvement in progression-free and overall survival (2), leading to FDA approval in 2011. However, responses are generally short lived (3–7 months; refs. 2–4), and novel approaches are needed. A small subset of patients maintain responses beyond 1 year, with little being known about what makes these cases unique.

There is intense research under way to identify strategies to improve the durability of response to BRAF-targeted therapy. This has led to therapeutic strategies combining BRAF-targeted therapy with other treatment modalities. One example of this is the concurrent administration of BRAF and MEK inhibitors, thus targeting two nodes within the same pathway. When the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib are combined, progression-free survival is extended, although most patients still progress on therapy within 10 months (5), yet again reinforcing the need for improving the durability of response.

Another area of success in the treatment of melanoma involves the use of immunotherapy. In particular, the use of immune checkpoint inhibitors has shown clear promise with the FDA approval of ipilimumab, a monoclonal antibody that blocks the immunomodulatory molecule cytotoxic T-lymphocyte antigen-4 (CTLA-4) on the surface of T lymphocytes, in 2011 (6). However, only 10% of patients achieve objective responses, with no more than 22% surviving beyond 3 years (7). Monoclonal antibodies targeting programmed death receptor-1 (PD-1; also known as CD279) and programmed death receptor ligand-1 (PD-L1; also known as B7-H1 or CD274) represent a further advance derived from inhibiting an immune checkpoint, with objective response rates ranging between 17% and 28% among the most promising agents (8, 9).

There is accumulating evidence indicating that the therapeutic efficacy of several agents relies on their ability to influence the tumor-host interaction, including the activation of an immune response specific for malignant cells (10). In this group, there are mounting data that oncogenic BRAF contributes to immune escape, and that targeting this

¹Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ²Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. ³Department of Medical Oncology, Massachusetts General Hospital and Harvard University, Boston, Massachusetts.

Corresponding Author: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-745-1553; Fax: 713-745-2436; E-mail: jwargo@mdanderson.org

doi: 10.1158/2159-8290.CD-14-0477

©2014 American Association for Cancer Research.
trials are not yet mature, and critical questions remain about empirically investigated in clinical trials. Results from these (12), which likely contributes to resistance to therapy. This provides evidence for combining BRAF-targeted therapy with immune checkpoint blockade, and this concept is being empirically investigated in clinical trials. Results from these trials are not yet mature, and critical questions remain about strategies combining these agents.

SUCCESSES AND LIMITATIONS OF BRAF-TARGETED THERAPY

The oncogenic BRAF^{V600E} mutation was originally described in melanoma (1), but has subsequently been identified as a driver mutation in several other cancers, including colon cancer, thyroid cancer, and hairy cell leukemia (1, 16, 17). Selective agents targeting this mutation were first tested in clinical trials for melanoma in 2008, demonstrating high response rates (~70%–80%; ref. 18) and a significant increase in survival when compared with then standard of care dacarbazine (leading to the FDA approval of vemurafenib in 2011; ref. 2). However, these high response rates were tempered with a short duration of response, with a median time to progression of approximately 6 months (2). Intense research efforts have focused on understanding resistance to BRAF inhibitors, with numerous resistance mechanisms identified in melanoma (19–26) and other cancers (27). Resistance is often mediated through reactivation of the MAPK pathway (e.g., via BRAF amplification, splice variants, and MEK mutations) but may also be mediated through stromal interactions (e.g., overproduction of HGF in the tumor microenvironment; ref. 21). Concomitant mutations in other signaling pathways have also been implicated in melanoma (such as PTEN; refs. 28, 29) and in other histologies (such as EGFR in colon cancer and thyroid cancer; refs. 27, 30), providing the rationale for combining BRAF-targeted therapy with other signal transduction inhibitors. These combination strategies have had some success in improving responses to therapy, although resistance is still a major issue. This is highlighted by the combination of dabrafenib with trametinib, which was approved by the FDA in early 2014 based on progression-free and overall survival benefit in comparison with either BRAF inhibitor alone or MEK inhibitor alone (5). Median progression-free survival was extended from less than 6 months with BRAF inhibitor monotherapy to 9.4 months with combined BRAF + MEK inhibition (5), and the percentage of patients alive at 1 year increased from 10% to 40% (BRAF inhibitor monotherapy vs. combined BRAF + MEK inhibition; ref. 5). However, the majority of patients still progress within a year, and there are very few complete responders (5). Nonetheless, this incremental benefit in survival provides a window of opportunity for treatment with other promising forms of therapy (such as immunotherapy), and there is emerging evidence that these strategies may be synergistic.

An important consideration in treatment with targeted therapy is the onset of tumor regression, which can be quite rapid. Metastatic lesions often demonstrate significant regression within 2 weeks of initiation of therapy, with associated symptomatic improvement. Tumor regression typically peaks by 4 months, with a median duration of response of 6 months. Thus, the slope is steep but responses are not prolonged (Fig. 1). Efforts to identify mechanisms to extend responses to targeted therapy are ongoing.

SUCCESSES AND LIMITATIONS OF IMMUNOTHERAPY

Immunotherapy is another treatment strategy for cancer, having demonstrated dramatic advances over the past several years. This strategy is not new, with high-dose IL2 having been approved by the FDA in 1998, based on its ability to produce durable responses in 6% to 10% of patients (31). Nonetheless, the use of high-dose IL2 is limited to specialized centers given its toxicity profile (32), and has a low overall response rate.

Another form of immunotherapy receiving recent “breakthrough” status for the treatment of melanoma and other cancers involves the use of immune checkpoint inhibitors (33). One of these agents is ipilimumab, a monoclonal antibody directed against the CTLA-4 molecule on the surface of T lymphocytes. CTLA-4 is an immunomodulatory molecule that functions to downregulate an immune response (34). Treatment with a monoclonal antibody that blocks this interaction (ipilimumab) relieves cytotoxic T lymphocytes from the inhibitory effects of CTLA-4, resulting in an enhanced immune response. Treatment with ipilimumab has shown an overall survival advantage in patients with advanced melanoma in a randomized, placebo-controlled trial (6) and received FDA approval in 2011. However, only 10% of patients obtain clear, objective responses, indicating that there is significant room for improvement. Other immune checkpoint inhibitors are in clinical trials and have shown promising results, including monoclonal antibodies blocking the immunomodulatory molecule PD-1 in the treatment of metastatic melanoma, which have shown response rates approaching 30% in a phase II clinical trial (8). Treatment with a monoclonal antibody blocking the ligand of this receptor, PD-L1, is also in clinical trials with similar response rates to those seen with PD-1 blockade (9). Interestingly, responses were also seen in other solid tumors, including renal cell carcinoma and non–small cell lung cancer (8). Mature response data were recently reported for PD-1 blockade with nivolumab demonstrating an estimated median overall survival of 16.8 months, with 1- and 2-year survival rates of 62% and 43%, respectively (35). The first agent targeting PD-1, pembrolizumab, was recently FDA-approved for metastatic melanoma in September 2014.

What is unique about immunotherapeutic approaches (compared with targeted therapy) is the potential to achieve long-term disease control in a significant proportion of patients (~6% for IL2, refs. 31 and 32; up to 22% for anti-CTLA-4, ref. 7). The mechanisms behind these durable responses are unclear, although they are being actively investigated in pretreatment and on-treatment tumor and blood
Combining Targeted Therapy and Immunotherapy

To date, the main limitation of immunotherapy is the fact that only a minority of patients will respond to therapy. This is in contrast with targeted therapy, in which a majority of patients achieve an objective response. However, despite a lower overall response rate, responses to immunotherapy tend to be more durable than those seen with targeted therapy. Tumor regression peaks later, although the median duration of response can be much longer (i.e., up to 2 years in the case of treatment with PD-1 blockade). This has tremendous relevance, and brings into question what the proper sequence of therapy should be in patients with metastatic melanoma harboring a BRAF mutation. Of note, disease burden plays a significant role in determining which therapy to initiate first—as the tempo of response to targeted therapy is more rapid than to immunotherapy. However, there is now growing evidence that immunotherapy may synergize with molecularly targeted therapy, suggesting that they be used in concert, with the potential for rapid tumor regression and durable response (Fig. 1). A current question in melanoma is whether targeted therapy–immunotherapy combination regimens should simply incorporate the most active individual components, or whether there are certain points of intervention that would synergize.

Figure 1. Representative response rates of targeted therapy, immunotherapy, and combined targeted therapy and immunotherapy. Plots representing the rate of response (left) and survival (right) after either targeted therapy (top), immunotherapy (middle), or the combination of the two (bottom). Top, the response and survival plots show typical responses to targeted therapy, with a deep but transient response rate and improved survival (compared with chemotherapy), but a "tail of the curve" approaching zero. This is in contrast with the response and survival plots in the middle for immunotherapy, with a more shallow but more durable response curve and improved survival (compared with chemotherapy) and a plateau in the "tail of the curve," suggesting the potential for long-term disease control. Bottom, proposed response and survival curves for combined targeted therapy and immunotherapy, with a deep and prolonged response rate, resulting in higher survival than either therapy alone and a higher "tail of the curve," with disease control in a much greater proportion of patients.
EVIDENCE FOR SYNERGY OF TARGETED THERAPY AND IMMUNOTHERAPY

There have been numerous previous links between onco-gene deaddiction and immunostimulation. In mouse models of T-cell acute lymphoblastic lymphoma and pro-B-cell leukemia, inactivation of MYC and BCR-ABL, respectively, required an intact immune system (specifically CD4⁺ T cells) for sustained tumor regression (36). Similarly, in gastrointestinal stromal tumors, the KIT tyrosine kinase inhibitor imatinib mesylate prolongs the survival of patients through direct effects on tumor cells and by indirect immunostimulatory effects on T and natural killer cells (37, 38). Similar findings in models of hepatocellular, breast, and liver cancers also support the role for immune-mediated tumor regression after gene deaddiction (39–42).

In melanoma, early evidence for potential synergy between targeted therapy and immunotherapy for melanoma was nested in the finding that oncogenic BRAF (BRAFV600E) can lead to immune escape in melanoma (43), and that blocking its activity via MAPK pathway inhibition leads to increased expression of melanocyte differentiation antigens (44). This was strengthened in the finding that targeted inhibition of the MAPK pathway leads to up to a 100-fold increase in expression of melanoma differentiation antigens in melanoma cell lines and fresh tumor digests in vitro, which conferred increased reactivity to antigen-specific T lymphocytes (11). The mechanism behind this seems to be related to transcriptional repression of microphthalmia-associated transcription factor (MITF) in the setting of oncogenic BRAF, with release of transcriptional repression when the MAPK pathway is blocked and subsequent expression of MITF targets (including the melanoma differentiation antigens MART-1, gp100, TRP-1, and TRP-2; ref. 11).

A critical component of this early work was the analysis of the effects of MAPK pathway inhibitors on T-lymphocyte function, because the MAPK pathway is known to be critical in T-cell activation and signaling. Importantly, “selective” inhibitors of BRAF V600E do not have any deleterious effect on T-cell function (11), and may even augment T-cell activation via paradoxical signaling through the RAS–GTP effect on T-cell function (11), and may even augment T-cell activation via paradoxical signaling through the RAS–GTP effect on T-cell function (11), and that blocking its activity via MAPK pathway inhibition leads to increased expression of melanocyte differentiation antigens (44). This was strengthened in the finding that targeted inhibition of the MAPK pathway leads to up to a 100-fold increase in expression of melanoma differentiation antigens in melanoma cell lines and fresh tumor digests in vitro, which conferred increased reactivity to antigen-specific T lymphocytes (11). The mechanism behind this seems to be related to transcriptional repression of microphthalmia-associated transcription factor (MITF) in the setting of oncogenic BRAF, with release of transcriptional repression when the MAPK pathway is blocked and subsequent expression of MITF targets (including the melanoma differentiation antigens MART-1, gp100, TRP-1, and TRP-2; ref. 11).

A critical component of this early work was the analysis of the effects of MAPK pathway inhibitors on T-lymphocyte function, because the MAPK pathway is known to be critical in T-cell activation and signaling. Importantly, “selective” inhibitors of BRAF V600E do not have any deleterious effect on T-cell function (11), and may even augment T-cell activation via paradoxical signaling through the RAS–GTP pathways (45). In contrast, MEK inhibitors demonstrate dose-dependent inhibition of T-cell function in vitro (11). This has relevance when contemplating the combination of BRAF-directed therapy with immunotherapy, as therapy including a MEK inhibitor may potentially have deleterious effects on T cells and thus may abrogate any potential synergy.

The first clinical evidence demonstrating potential synergy of BRAF-targeted therapy and immunotherapy came from two independent groups, which demonstrated enriched T-cell infiltrates in tumors of patients with metastatic melanoma within 14 days of the initiation of BRAF inhibitor therapy (ref. 13; Fig. 2). This was associated with an increase in melanoma antigen expression in tumors (Fig. 2) and a decrease in VEGF (15) and the immunosuppressive cytokines IL6 and IL8 (12). The tumor stroma seems to play a critical role, as stromal cell-mediated immunosuppression via IL1 is induced by oncogenic BRAF and blocked with BRAF inhibitors (14). Of note, these changes are lost at the time of progression (12).

Equally profound and clinically impactful is the observation of increased expression of immunomodulatory mol-
Several preclinical models have been used to study the hypothesis that BRAF-targeted therapy will synergize with immunotherapy. Results of these studies have been mixed, with all (15, 50–52) but one (53) showing synergy. Our own group has studied combined BRAF-targeted therapy and immune checkpoint blockade against the PD-1 pathway, and observed synergy when these two strategies are combined (52). These models are useful, and studies exploring multiple aspects of combination approaches (e.g., appropriate sequence and timing of therapy) should be performed to improve decision making in the design of clinical trials. The number of immune-competent melanoma models remains limited, and this ultimately weakens the ability to thoroughly vet the most pressing questions about prioritization of agents, doses, and schedules preclinically.

There are growing data about the role of the tumor microenvironment in response and resistance to therapy (12, 14, 21), with the potential to target stromal cells (such as tumor-associated fibroblasts, endothelial cells, and macrophages or regulatory T cells) to improve responses. Additional insight about the contribution of each of these stromal components in response to monotherapy is critical in instructing how they may be used in combination for clinical trials, although preclinical in vitro models (such as high-throughput screening assays) and murine models may also be instructive.

CONSIDERATIONS IN COMBINING THESE STRATEGIES

On the basis of promising results from preclinical and clinical studies demonstrating potential synergy between immunotherapy and targeted therapy for melanoma (11, 12, 15, 50–52), clinical trials are under way to investigate the efficacy and safety of combining targeted therapy and immunotherapy in patients with BRAF mutation–positive melanoma (54). In these trials, BRAF and/or MEK inhibitors are being combined with several forms of immunotherapy—including cytokines (IL2), immune checkpoint inhibitors (against CTLA-4, PD-1, or PD-L1), and adoptive cell therapy (with tumor-infiltrating lymphocytes [TIL]). Mature response and toxicity data are not yet available; however, interesting data have been extracted from these trials (as well as from preclinical and clinical studies) that raise important considerations when combining these strategies.

One consideration is the issue of added toxicity in the setting of combined BRAF-targeted therapy and immunotherapy. This is relevant, as initial efforts in clinical trials using ipilimumab in combination with BRAF-targeted therapy were limited by this variable (55). In this trial, patients with metastatic melanoma with known BRAFV600E mutation received a 1-month run in with a BRAF inhibitor (vemurafenib) alone followed by four infusions of ipilimumab. The primary goal of this trial was to assess safety, and the target accrual was 50 patients, although the trial was stopped early due to toxicity. Specifically, hepatotoxicity was observed in a substantial proportion of patients, consisting mainly of grade 2 or 3 elevations in liver function tests (LFT; ref. 55). Although these elevations in LFTs were completely asymptomatic and resolved when therapy was discontinued or with administration of systemic steroids, these data highlight the potential for unexpected toxicity and mandate that careful attention be paid when combining these agents. A similar trial is now under way with sequential (i.e., nonoverlapping) administration of these agents. Trials combining other BRAF-targeted agents (e.g., dabrafenib) with immune checkpoint inhibitors are also under way, and have not shown the same toxicity profile, although data are not mature. Toxicity with immune checkpoint blockade monotherapy targeting PD-1 and PD-L1 is significantly lower than that seen with therapy targeting CTLA-4 (6, 8, 9), but it is unclear whether this will translate when used in combination with BRAF inhibitor therapy. Trials combining these agents are also under way.

Another important consideration is whether synergy will be seen when immunotherapy is combined with other forms of MAPK pathway blockade (e.g., MEK inhibitors), given that MAPK pathway activity is critical to T-cell activation and may abrogate T-cell responses (11). For each of the established targeted therapies relevant to other cancer subpopulations, similar concerns pertain to effect on the immune cell population, but have not been systemically investigated. We studied this in vitro, and demonstrated that although treatment with a MEK inhibitor resulted in increased melanoma antigen expression in both wild-type and mutant BRAF cell lines, it also resulted in impaired T-cell proliferation and function. Namely, the increased reactivity to antigen-specific T cells conferred by increased antigen expression was completely abrogated with MEK inhibition (11). This issue is particularly relevant in light of recent data showing that responses to combined BRAF–MEK inhibition were superior to those seen with BRAF monotherapy (5), leading to the FDA approval of this combination regimen in 2014. However, it is important to note that no clear differences were observed with regard to the number of infiltrating T lymphocytes in patients receiving combined BRAF–MEK inhibitor therapy versus BRAF inhibitor monotherapy (12), suggesting that the MEK-mediated T-cell inhibition observed in our in vitro studies may not be clinically relevant. Studies are currently under way in murine models to help answer this question, and clinical trials combining BRAF and MEK inhibitors with immune checkpoint inhibitors are also ongoing. Although the primary endpoints of these initial studies are safety and tolerability, secondary endpoints will focus on disease control rates and correlative studies in which a thoughtful analysis of pretreatment and on-treatment tumor biopsy samples will be performed to gain insight into this important question.

A related consideration in combining these strategies includes the proper sequence and timing of regimens. This is likely a critical factor, although we do not yet have a comprehensive understanding of the optimal sequence and timing when BRAF-targeted therapy is combined with immunotherapy. Nonetheless, insights do exist, and additional studies are under way to illuminate this point. Early data suggest that the immune response to BRAF inhibitors happens fairly quickly (within 10–14 days of initiation of a BRAF inhibitor) but is transient, with very few T cells remaining a month after initiation of therapy (12). Thus, there may be a narrow window to optimize recruitment and activation of T lymphocytes in the setting of BRAF-targeted therapy. The hypothesis based on this early work would propose that BRAF inhibitor therapy be initiated with a short lead-in...
(e.g., 2 weeks) followed by the addition of immunotherapy. A corollary to this hypothesis would suggest that an immune checkpoint inhibitor (specifically targeting the PD-1 pathway) should be included in this regimen, given upregulation of PD-L1 in the tumor microenvironment within 2 weeks of initiation of BRAF-targeted therapy (12). Another finding from these studies suggests that the beneficial changes to the tumor microenvironment induced by treatment with a BRAF inhibitor are transient and are essentially absent at 4 weeks, with reversion to a more hostile microenvironment at the time of progression (12). Thus, the appropriate timing to add an immunomodulatory agent to the regimen is early during the treatment rather than at the time of progression (Fig. 3), a concept that is supported by the observation that patients who are treated with ipilimumab after progression on BRAF inhibitors exhibit a poor response rate to therapy (56). Nonetheless, these suggestions are based on limited data and are speculative, and need to be validated with other targeted agents and combination regimens. Studies are currently under way to elaborate on this point, both in the context of in vivo murine models and in carefully planned correlative studies in combination clinical trials. Both the timing and sequence of therapy will be addressed in these studies.

Figure 3. Sequence and timing considerations for combining targeted therapy (TT) and immunotherapy (IT). The plots show proposed changes in immune infiltrate and expression of immunomodulatory molecules/cytokines/VEGF, depending on the sequence of treatment with targeted therapy and immunotherapy. With targeted therapy, there is an early but transient increase in immune infiltrate that is associated with a transient decrease in immunosuppressive cytokines, but an increase in PD-1 and PD-L1. Treatment with immunotherapy results in a more gradual and prolonged increase in immune infiltrate, and is also associated with an increase in PD-1 and PD-L1. The addition of targeted therapy at the time of progression on immunotherapy may not lead to synergy given the kinetics of these changes in the tumor microenvironment. Likewise, the addition of immunotherapy at the time of progression to targeted therapy may not lead to synergy, for similar reasons. However, the concurrent use of targeted therapy and immunotherapy simultaneously may promote a favorable microenvironment along with T-cell activation, with the potential for synergy and prolonged responses.

UNANSWERED QUESTIONS

A key question when examining the immune effects of BRAF inhibitors and their related potential synergy with
Combining Targeted Therapy and Immunotherapy

immunotherapeutic strategies is whether or not this represents an antigen-specific response. There are data suggesting that this is, at least in part, the case, as treatment with BRAF inhibitors results in increased melanoma antigen expression by tumors (12) and a more clonal T-cell response (58). However, it is very unlikely that this is purely due to a response to melanoma differentiation antigens, as multiple other changes in the tumor microenvironment (namely, a decrease in immunosuppressive cytokines and VEGF) likely facilitate recruitment and proliferation of T cells in the context of treatment with a BRAF inhibitor (12).

One intriguing possibility is that T-cell responses against other antigens (namely, neoantigens) play a significant role in the response to BRAF inhibition. There are data to support the role of reactivity to neoantigens in melanoma, as T cells recognizing these antigens are associated with response to therapy in the context of treatment with TILs (59) and immune checkpoint blockade (60). Although neoantigens have been studied in a small subset of patients, larger cohorts are clearly needed to better understand their role in response to therapy and the potential use of T cells targeting these antigens for personalized cancer therapy.

Another question is which form of immunotherapy should be used in combination with targeted therapy. Although early efforts have focused on combining BRAF-targeted therapy with FDA-approved agents (such as IL2 and ipilimumab), subsequent trials have combined these strategies with immunotherapeutic strategies still in clinical trials (such as PD-1 and PD-L1). This adds a layer of complexity, as response rates and toxicity with these agents may be more difficult to interpret because definitive estimates of benefit from the newer agents are lacking. In addition, novel agents currently in development or in early-stage clinical trials (such as monoclonal antibodies targeting TIM-3) will soon be added to the armamentarium for combination strategies, and we have little insight into the optimal mode of stimulating immune effector cells in the setting of “priming” by targeted therapies.

In addition to immunotherapy, numerous other strategies may be added to a backbone of BRAF-targeted therapy and immunotherapy with the goal of further enhancing responses. An example of this is radiotherapy—a modality reported to have potential synergy with both targeted therapy (61) and immunotherapy (62). The potential benefit of this strategy hinges on the abscopal effect—a phenomenon in which tumors regress at sites remote from an irradiated target (61, 63, 64). This is likely related to increased antigen presentation and enhanced killing by T cells (61). Radiotherapy is being used in combination with immunotherapy in clinical trials, and holds potential to augment responses to combined BRAF-targeted therapy and immunotherapy as well.

EXTENDING THESE CONCEPTS TO OTHER CANCERS

There is growing evidence that similar combination strategies may be used to enhance responses to therapy for non-melanoma malignancies. For these combinatorial strategies to work, the targeted therapy must be able to inhibit pertinent oncogenic events, resulting in a more favorable tumor microenvironment for the antitumor immune response. In addition, targeted therapies should not inhibit critical immune effector cells and should rather potentiate or stimulate an inactive effector immune population (65). Similar to BRAF inhibitors in melanoma, ABL and c-KIT inhibitors have had great success in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors (GIST) (66, 67). T cells have been found to be a crucial component of the antitumor effect after imatinib treatment in GIST, activating CD8+ T cells while inducing regulatory T-cell apoptosis within the tumor (37). Another potential target is the PI3K pathway, as glioblastoma multiforme cells with a PTEN deficiency have an increase in PD-L1 expression that can be reversed following PI3K inhibition (68). In addition, EGFR-driven lung tumors have recently been shown to inhibit antitumor immunity by activation of the PD-1–PD-L1 pathway (69). Accordingly, using a combination of PD-1 blockade and EGFR tyrosine kinase inhibitors has been suggested as a promising strategy to extend the durability of treatment and delay disease progression (69). As the genomic era and the data of the first generation of targeted therapy mature, our ability to extend the concept of combined immunotherapy and targeted therapy to other histologies will continue to grow. The key now is to identify compounds that may show synergy with immunotherapy, and high-throughput screening assays are currently in development.

IMPLICATIONS FOR RESEARCH AND CLINICAL TRIALS

The concept of potential synergy with BRAF-targeted therapy and immunotherapy is being empirically investigated in clinical trials; however, much remains to be learned. Response data from these initial trials are not mature, and additional trials will be needed to determine the appropriate sequence, schedule, and duration of therapy if there is evidence of synergy. If not, a careful analysis of data should be performed before discarding this concept (including a thoughtful analysis of tumor and blood samples), as dosing and schedule may factor into these early trials.

In addition to optimizing sequence schedule and duration, new agents are becoming available on both the targeted therapy and the immunotherapy fronts. Novel targeted agents (e.g., against MEK, CDK4, PI3K, MDM2, FGFR, and c-MET) and immunotherapeutic approaches (e.g., against TIM-3, LAG-3, GITR, OX40, and CD27) are now available and are in clinical trials, and could also be used in combination. In addition to combination “doublets,” trials are also now ongoing that combine three different agents (such as BRAF and MEK inhibitors with an immune checkpoint inhibitor). Thus, these combination strategies are becoming increasingly complex, with a large number of potential combinations/schedules that must be carefully considered. Methods to predict success of potential combinations in the setting of an intact immune system are critically needed, and are in development.

An additional consideration in designing these trials is potential toxicity when used in combination. An example of this is hepatotoxicity, which was observed when patients were treated with vemurafenib and ipilimumab (55). The mechanism behind this is not entirely understood, although
it mandates thorough investigation, as insights gained may shed light on other potential toxicities and will help guide the development of subsequent clinical trials.

Of paramount importance in the development of these trials is the incorporation of longitudinal blood and tumor sampling into the treatment schema. This allows for the validation of target inhibition as well as for critical correlative studies that will ultimately allow for biomarker discovery. Serial biopsies and blood draws are now often mandated by industry-sponsored trials to drive their own biomarker discovery, and provide an opportunity for additional research to better understand mechanisms of response and resistance to therapy.

In addition to clinical trials, there are tremendous opportunities for research in preclinical studies using in vitro techniques and murine models. Importantly, there is now a shift toward incorporating immune cells for in vitro screening methods and incorporating murine models with intact immune systems in an effort to determine the anticancer and immune effects of single agents or combination therapies. These techniques and models have gained traction and should lead to an improved prediction of efficacy in clinical trials.

CONCLUSIONS

There is evidence for potential synergy of targeted therapy and immunotherapy; however, significant inroads must be made to optimize combination approaches to maximize responses and limit toxicity. A better understanding of the mechanisms of response and resistance to each of these forms of therapy is critical to instruct how best to combine therapeutic agents. Central to this understanding is translational research conducted on patient samples, which may inform (and be informed by) parallel in vivo and murine studies. However, this clearly represents a changing paradigm in cancer treatment, with a critical understanding of the interplay between genomics and antitumor immunity.

Disclosure of Potential Conflicts of Interest

J.A. Wargo has received honoraria from the speakers’ bureau of Dava Oncology. K.T. Flaherty is a consultant/advisory board member for GlaxoSmithKline, Roche/Genentech, and Novartis. No potential conflicts of interest were disclosed by the other author.

Grant Support

J.A. Wargo acknowledges NIH grant 1K08CA160692-01A1 and the generous philanthropic support of several families whose lives have been affected by melanoma. J.A. Wargo and K.T. Flaherty acknowledge NIH grant U54CA163125-01.

Received May 8, 2014; revised August 14, 2014; accepted August 25, 2014; published OnlineFirst November 13, 2014.

REFERENCES

Combining Targeted Therapy and Immunotherapy


64. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An absco-
pal response to radiation and ipilimumab in a patient with metastatic
65. Begley J, Ribas A. Targeted therapies to improve tumor immuno-
66. Blanke CD, Rankin C, Demetri GD, Ryan CW, vonMehren M, Ben-
jamin RS, et al. Phase III randomized, intergroup trial assessing
imatinib mesylate at two dose levels in patients with unresectable or
metastatic gastrointestinal stromal tumors expressing the kit recep-
67. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H,
Gattermann N, et al. Five-year follow-up of patients receiving
2408–17.
Loss of tumor suppressor PTEN function increases B7-H1 expression
CL, et al. Activation of the PD-1 pathway contributes to immune escape
# Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

Jennifer A. Wargo, Zachary A. Cooper and Keith T. Flaherty

*Cancer Discovery* 2014;4:1377-1386. Published OnlineFirst November 13, 2014.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi: <a href="http://cancerdiscovery.aacrjournals.org/content/4/12/1377.full#ref-list-1">10.1158/2159-8290.CD-14-0477</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 67 articles, 27 of which you can access for free at: <a href="http://cancerdiscovery.aacrjournals.org/content/4/12/1377.full#ref-list-1">http://cancerdiscovery.aacrjournals.org/content/4/12/1377.full#ref-list-1</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Citing articles</th>
<th>This article has been cited by 5 HighWire-hosted articles. Access the articles at: <a href="http://cancerdiscovery.aacrjournals.org/content/4/12/1377.full#related-urls">http://cancerdiscovery.aacrjournals.org/content/4/12/1377.full#related-urls</a></th>
</tr>
</thead>
</table>

### E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

### Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

### Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.